United Therapeutics (NASDAQ:UTHR) CEO Martine Rothblatt Sells 9,500 Shares of Stock

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 9,500 shares of the stock in a transaction dated Wednesday, September 2nd. The stock was sold at an average price of $493.46, for a total value of $4,687,870.00. Following the transaction, the chief executive officer directly owned 324,443 shares in the company, valued at approximately $160,099,642.78. The trade was a 2.84% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

United Therapeutics Price Performance

Shares of United Therapeutics stock opened at $490.24 on Friday. The stock has a market capitalization of $21.03 billion, a price-to-earnings ratio of 17.54, a price-to-earnings-growth ratio of 2.46 and a beta of 0.56. The business has a 50-day moving average of $527.06 and a 200 day moving average of $539.91. United Therapeutics Corporation has a 12 month low of $375.61 and a 12 month high of $609.35.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings results on Wednesday, August 5th. The biotechnology company reported $7.27 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $6.86 by $0.41. United Therapeutics had a net margin of 41.56% and a return on equity of 20.18%. The company had revenue of $783.30 million for the quarter, compared to analyst estimates of $804.65 million. During the same period in the prior year, the firm earned $6.41 earnings per share. The business’s revenue for the quarter was down 1.9% compared to the same quarter last year. Equities research analysts anticipate that United Therapeutics Corporation will post 26.33 earnings per share for the current year.

Institutional Investors Weigh In On United Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the business. Toth Financial Advisory Corp boosted its holdings in United Therapeutics by 2,400.0% in the second quarter. Toth Financial Advisory Corp now owns 50 shares of the biotechnology company’s stock valued at $27,000 after purchasing an additional 48 shares in the last quarter. Fiduciary Financial Advisors acquired a new stake in United Therapeutics during the second quarter worth approximately $30,000. WealthCollab LLC lifted its position in shares of United Therapeutics by 55.9% during the 2nd quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock worth $30,000 after buying an additional 38 shares during the last quarter. Rakuten Securities Inc. lifted its position in shares of United Therapeutics by 76.7% during the 2nd quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company’s stock worth $30,000 after buying an additional 46 shares during the last quarter. Finally, Entrust Financial LLC acquired a new position in shares of United Therapeutics in the 4th quarter valued at $31,000. Institutional investors and hedge funds own 94.08% of the company’s stock.

Trending Headlines about United Therapeutics

Here are the key news stories impacting United Therapeutics this week:

• Positive Sentiment: The FDA accepted United Therapeutics’ supplemental new drug application seeking to expand the label for nebulized Tyvaso to treat idiopathic pulmonary fibrosis (IPF). The filing is supported by Phase 3 TETON-1 and TETON-2 data, which showed statistically significant lung-function improvement and reduced clinical worsening. FDA review is expected to conclude in late April 2027. A successful expansion could substantially increase Tyvaso’s addressable market. FDA Accepts UTHR’s sNDA for Tyvaso in Idiopathic Pulmonary Fibrosis
• Neutral Sentiment: Analyst sentiment remains broadly favorable, with United Therapeutics carrying a consensus “Moderate Buy” rating and an average price target of about $646, although some firms have reduced their targets and Morgan Stanley’s target is near the current trading range. This signals long-term optimism but also highlights valuation and execution concerns.
• Negative Sentiment: CEO Martine Rothblatt sold 9,500 shares for approximately $4.69 million, reducing her direct ownership by 2.84%. EVP Paul Mahon separately sold 8,300 shares for about $4.00 million, cutting his position by 15.52%. The transactions may reinforce near-term investor caution, although Rothblatt’s sale was disclosed as occurring under a pre-arranged trading plan. United Therapeutics Insider Sale Filing
• Negative Sentiment: United Therapeutics’ second-quarter results showed Tyvaso revenue declining 4% year over year, with management citing competition across nebulized Tyvaso, Tyvaso DPI and Remodulin. The IPF opportunity is strategically important because investors are looking for growth to offset weakness in the existing pulmonary hypertension business.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on UTHR shares. Bank of America cut their price objective on United Therapeutics from $620.00 to $613.00 and set a “neutral” rating on the stock in a research report on Friday, July 10th. Wells Fargo & Company raised United Therapeutics from an “equal weight” rating to an “overweight” rating and boosted their target price for the stock from $575.00 to $735.00 in a research note on Thursday, May 7th. Weiss Ratings downgraded shares of United Therapeutics from a “buy (b)” rating to a “buy (b-)” rating in a research note on Thursday, August 27th. Morgan Stanley set a $515.00 price target on shares of United Therapeutics in a report on Thursday, August 6th. Finally, JPMorgan Chase & Co. raised their price objective on shares of United Therapeutics from $685.00 to $687.00 and gave the company an “overweight” rating in a report on Thursday, July 23rd. Eleven equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat.com, United Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $646.00.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.